{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:53:32Z","timestamp":1792000412962,"version":"4.4.0"},"reference-count":216,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ctrv.2024.102807","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T10:43:58Z","timestamp":1722595438000},"page":"102807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape"],"prefix":"10.1016","volume":"130","author":[{"given":"Michael","family":"Weller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Vollmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K.","family":"Brastianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"\u00d6hrling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Hegi-Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102807_b0005","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2014.01.006","article-title":"EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?","volume":"84","author":"Hendriks","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/nou099","article-title":"Incidence of brain metastasis at initial presentation of lung cancer","volume":"17","author":"Villano","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0020","article-title":"Advances in lung cancer driver genes associated with brain metastasis","volume":"10","author":"Kang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.12.005","article-title":"Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years","volume":"162","author":"Steindl","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0035","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0040","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2021.07.032","article-title":"The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy","volume":"156","author":"Karschnia","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0050","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0055","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3390\/cancers15123193","article-title":"PRO: Do we still need whole-brain irradiation for brain metastases?","volume":"15","author":"Popp","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102807_b0060","first-page":"1","article-title":"Emerging systemic treatment perspectives on brain metastases: Moving toward a better outlook for patients","volume":"42","author":"Alvarez-Breckenridge","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ctrv.2024.102807_b0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1470-2045(21)00696-3","article-title":"Should radiotherapy be considered for the initial treatment of brain metastases?","volume":"23","author":"Minniti","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0070","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.21.01715","article-title":"Managing central nervous system spread of lung cancer: The state of the art","volume":"40","author":"Tsui","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0075","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/neuonc\/noac118","article-title":"Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions","volume":"24","author":"Aizer","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0080","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaoncol.2021.1359","article-title":"Central nervous system-specific outcomes of phase 3 randomized clinical trials in patients with advanced breast cancer, lung cancer, and melanoma","volume":"7","author":"Corbett","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103460","article-title":"Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review","volume":"166","author":"Schoenmaekers","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2024.102807_b0090","unstructured":"European Thoracic Oncology Platform. 19-21 USZ-STRIKE, https:\/\/www.etop-eu.org\/index.php?option=com_content&view=article&id=115687:19-21-usz-strike&catid=408&Itemid=1473; 2022 [accessed February 2023]."},{"key":"10.1016\/j.ctrv.2024.102807_b0095","unstructured":"US National Library of Medicine. ClinicalTrials.gov [Website], https:\/\/clinicaltrials.gov\/; [accessed October 2023]."},{"key":"10.1016\/j.ctrv.2024.102807_b0100","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1002\/cam4.2577","article-title":"Operative and peri-operative considerations in the management of brain metastasis","volume":"8","author":"Sankey","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2024.102807_b0105","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1002\/cncr.32372","article-title":"Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036)","volume":"125","author":"Wang","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.912505","article-title":"Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0115","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2024.102807_b0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2013.10.004","article-title":"High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer","volume":"83","author":"Preusser","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41588-020-0592-7","article-title":"Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma","volume":"52","author":"Shih","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2024.102807_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.951805","article-title":"Clinical determinants impacting overall survival of patients with operable brain metastases from non-small cell lung cancer","volume":"12","author":"Piffko","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0135","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3171\/2014.9.JNS13939","article-title":"Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis","volume":"122","author":"Patel","year":"2015","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2024.102807_b0140","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3171\/JNS\/2008\/108\/2\/0248","article-title":"Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa","volume":"108","author":"Suki","year":"2008","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2024.102807_b0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40644-019-0250-4","article-title":"Neurosurgical applications of MRI guided laser interstitial thermal therapy (LITT)","volume":"19","author":"Salem","year":"2019","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.ctrv.2024.102807_b0150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2024.102807_b0155","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ijrobp.2009.06.006","article-title":"Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery","volume":"77","author":"Blonigen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102807_b0160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0165","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/neuonc\/nox090","article-title":"Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis","volume":"19","author":"Narloch","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0170","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00066-022-01994-3","article-title":"Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis","volume":"198","author":"Bernhardt","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ctrv.2024.102807_b0175","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fonc.2018.00336","article-title":"Brain radiation necrosis: current management with a focus on non-small cell lung cancer patients","volume":"8","author":"Loganadane","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0180","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0185","doi-asserted-by":"crossref","first-page":"ii38","DOI":"10.1093\/neuonc\/now301","article-title":"The radiosurgery fractionation quandary: single fraction or hypofractionation?","volume":"19","author":"Kirkpatrick","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0190","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","article-title":"Single-fraction versus multifraction (3 x 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: A comparative analysis of local control and risk of radiation-induced brain necrosis","volume":"95","author":"Minniti","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102807_b0195","doi-asserted-by":"crossref","first-page":"559193","DOI":"10.3389\/fonc.2020.559193","article-title":"FSRT vs. SRS in brain metastases-differences in local control and radiation necrosis - A volumetric study","volume":"10","author":"Putz","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0200","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3171\/2017.3.JNS162532","article-title":"Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases \u22652 cm","volume":"129","author":"Angelov","year":"2018","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2024.102807_b0205","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1186\/s12885-022-10083-8","article-title":"Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1\u20134 brain metastases","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.prro.2011.12.004","article-title":"Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline","volume":"2","author":"Tsao","year":"2012","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0215","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11864-013-0258-0","article-title":"Treatment of brain metastases in lung cancer: strategies to avoid\/reduce late complications of whole brain radiation therapy","volume":"14","author":"Shaw","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0220","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102807_b0225","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/1759-7714.13359","article-title":"Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status","volume":"11","author":"Arrieta","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0230","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase III Trial NRG Oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0235","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC.3): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0240","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0245","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13014-021-01802-9","article-title":"Current status and recent advances in resection cavity irradiation of brain metastases","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0250","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1227\/NEU.0000000000001096","article-title":"Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases: A multi-institutional analysis","volume":"79","author":"Patel","year":"2016","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ctrv.2024.102807_b0255","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.972727","article-title":"Preoperative stereotactic radiosurgery in the management of brain metastases and gliomas","volume":"9","author":"Lehrer","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.ctrv.2024.102807_b0260","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3389\/fneur.2018.00959","article-title":"Preoperative stereotactic radiosurgery for brain metastases","volume":"9","author":"Routman","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.ctrv.2024.102807_b0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ctrv.2024.102807_b0270","doi-asserted-by":"crossref","first-page":"12654","DOI":"10.3390\/ijms222312654","article-title":"Blood-brain barrier in brain tumors: Biology and clinical relevance","volume":"22","author":"Mo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102807_b0275","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2024.102807_b0280","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/jm301297f","article-title":"Demystifying brain penetration in central nervous system drug discovery. Miniperspective","volume":"56","author":"Di","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2024.102807_b0285","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.3390\/pharmaceutics14102231","article-title":"Harnessing ultrasound for targeting drug delivery to the brain and breaching the blood-brain tumour barrier","volume":"14","author":"Barzegar-Fallah","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ctrv.2024.102807_b0290","first-page":"v133","article-title":"Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases","volume":"3","author":"Blethen","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ctrv.2024.102807_b0295","doi-asserted-by":"crossref","first-page":"8846","DOI":"10.3390\/curroncol29110696","article-title":"Focused delivery of chemotherapy to augment surgical management of brain tumors","volume":"29","author":"Mehkri","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0300","doi-asserted-by":"crossref","first-page":"8267","DOI":"10.1038\/s41598-018-26636-6","article-title":"Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a","volume":"8","author":"Tiwary","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2024.102807_b0305","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ctrv.2014.03.005","article-title":"Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases","volume":"40","author":"Zimmermann","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102807_b0310","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0315","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1634\/theoncologist.2017-0572","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for central nervous system metastases from non-small cell lung cancer","volume":"23","author":"Ahluwalia","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102807_b0320","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fonc.2018.00088","article-title":"Brain metastases in oncogene-addicted non-small cell lung cancer patients: Incidence and treatment","volume":"8","author":"Remon","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0325","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.3390\/cells10102620","article-title":"Research progress and challenges in the treatment of central nervous system metastasis of non-small cell lung cancer","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ctrv.2024.102807_b0330","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0335","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.jtho.2021.07.026","article-title":"A phase II study of osimertinib for radiotherapy-naive central nervous system metastasis from NSCLC: Results for the T790M cohort of the OCEAN Study (LOGIK1603\/WJOG9116L)","volume":"16","author":"Yamaguchi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0340","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0345","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ijc.33904","article-title":"Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis","volume":"150","author":"Zhao","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0350","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer","volume":"42","author":"Janne","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0355","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: Results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0360","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.jtho.2023.08.017","article-title":"Central nervous system outcomes of lazertinib versus gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis","volume":"18","author":"Soo","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0365","unstructured":"AbbVie. AbbVie announces U.S. FDA granted breakthrough therapy designation (BTD) to telisotuzumab vedotin (Teliso-V) for previously treated non-small cell lung cancer, https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-announces-us-fda-granted-breakthrough-therapy-designation-btd-to-telisotuzumab-vedotin-teliso-v-for-previously-treated-non-small-cell-lung-cancer.htm; 2022 [accessed February 2023]."},{"key":"10.1016\/j.ctrv.2024.102807_b0370","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1200\/JCO.2017.77.5841","article-title":"Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials","volume":"36","author":"Camidge","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0375","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: Final results of Phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0380","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","article-title":"Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: Results from ASCEND-2","volume":"34","author":"Crino","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0385","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0390","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0395","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102807_b0400","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102807_b0405","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jtho.2024.01.013","article-title":"Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase 3 study (INSPIRE)","volume":"19","author":"Shi","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0410","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2024.102807_b0415","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0420","first-page":"JCO2400581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0425","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN Study","volume":"40","author":"Solomon","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0430","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 Trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102807_b0435","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0440","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: Updated safety and efficacy from the registrational LIBRETTO-001 Phase I\/II Trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0445","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtho.2023.01.008","article-title":"Central nervous system disease in patients with RET fusion-positive NSCLC treated with selpercatinib","volume":"18","author":"Murciano-Goroff","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0450","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ctrv.2024.102807_b0455","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.ctrv.2024.102807_b0460","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S1556-0864(23)00268-X","article-title":"Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC) [Abstract 14MO]","volume":"18","author":"Li","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0465","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102807_b0470","doi-asserted-by":"crossref","unstructured":"Garon E.B., Heist R.S., Seto T., Han J.-Y., Reguart N., Groen H.J., et al. Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM). Cancer Res 2020;80(16_Suppl):CT082. https:\/\/doi.org\/10.1158\/1538-7445.AM2020-CT082.","DOI":"10.1158\/1538-7445.AM2020-CT082"},{"issue":"Suppl","key":"10.1016\/j.ctrv.2024.102807_b0475","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jtho.2022.07.024","article-title":"Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Primary analysis of the confirmatory VISION Cohort C [Abstract OA03.05]","volume":"17","author":"Thomas","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0480","doi-asserted-by":"crossref","first-page":"e2100418","DOI":"10.1200\/PO.21.00418","article-title":"Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107442","article-title":"Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer","volume":"188","author":"Cho","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0490","unstructured":"European Medicines Agency. Lumykras (sotorasib), https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lumykras; 2022 [accessed February 2023]."},{"key":"10.1016\/j.ctrv.2024.102807_b0495","unstructured":"US Food and Drug Administration. LUMAKRAS (sotorasib) US prescribing information, https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Lumakras\/lumakras_pi_hcp_english.pdf; 2023 [accessed February 2023]."},{"key":"10.1016\/j.ctrv.2024.102807_b0500","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc; 2022 [accessed February 2023]."},{"key":"10.1016\/j.ctrv.2024.102807_b0505","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"Janne","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102807_b0510","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102807_b0515","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102807_b0520","doi-asserted-by":"crossref","unstructured":"Dingemans A.-M.C., Syrigos K., Livi L., Paulus A., Kim S.-W., Chen Y., et al. Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT). J Clin Oncol 2023;41(Suppl 17):LBA9016.","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9016"},{"key":"10.1016\/j.ctrv.2024.102807_b0525","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRAS(G12C)-mutated non-small-cell lung cancer who have untreated CNS metastases","volume":"41","author":"Negrao","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0530","unstructured":"Daiichi Sankyo. Patritumab deruxtecan granted U.S. FDA breakthrough therapy designation in patients with metastatic EGFR-mutated non-small cell lung cancer, https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202112\/20211223_E1.pdf; 2021 [accessed February 2023]."},{"key":"10.1016\/j.ctrv.2024.102807_b0535","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"Janne","year":"2022","journal-title":"Cancer Discov"},{"issue":"Suppl 16","key":"10.1016\/j.ctrv.2024.102807_b0540","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1200\/JCO.2022.40.16_suppl.9016","article-title":"Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met\u2013overexpressing (OE) advanced non-small cell lung cancer (NSCLC)","volume":"40","author":"Camidge","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0545","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung; 2022 [accessed July 2023]."},{"key":"10.1016\/j.ctrv.2024.102807_b0550","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2024.102807_b0555","doi-asserted-by":"crossref","first-page":"S762","DOI":"10.1016\/j.annonc.2023.09.2354","article-title":"1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non\u2013small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02","volume":"34","author":"Li","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0560","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor\u2013mutated non\u2013small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0565","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00262-021-03031-1","article-title":"Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials","volume":"71","author":"Landre","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2024.102807_b0570","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1038\/s41467-021-25860-5","article-title":"Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases","volume":"12","author":"Prakadan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2024.102807_b0575","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update","volume":"6","author":"Reck","year":"2021","journal-title":"ESMO Open"},{"issue":"Suppl 7","key":"10.1016\/j.ctrv.2024.102807_b0580","doi-asserted-by":"crossref","first-page":"S1430","DOI":"10.1016\/j.annonc.2021.10.141","article-title":"Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1 [Abstract 122MO]","volume":"32","author":"Reck","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0585","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0590","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jtho.2023.01.083","article-title":"Efficacy, safety, and health-related quality of life with camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced nonsquamous NSCLC with brain metastases (CAP-BRAIN): A multicenter, open-label, single-arm, phase 2 study","volume":"18","author":"Hou","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0595","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1200\/JCO.22.02561","article-title":"Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (atezo-brain, GECP17\/05)","volume":"41","author":"Nadal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0600","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/JTO.0000000000000587","article-title":"Central nervous system pseudoprogression in a patient treated with PD-1 checkpoint inhibitor","volume":"10","author":"Doherty","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0605","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.3390\/cancers13143407","article-title":"Immunotherapy in non-small cell lung cancer patients with brain metastases: Clinical challenges and future directions","volume":"13","author":"Pathak","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102807_b0610","doi-asserted-by":"crossref","first-page":"e1057388","DOI":"10.1080\/2162402X.2015.1057388","article-title":"Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases","volume":"5","author":"Berghoff","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2024.102807_b0615","doi-asserted-by":"crossref","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","article-title":"Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking","volume":"115","author":"Taggart","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2024.102807_b0620","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102807_b0625","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0630","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0635","first-page":"6","article-title":"Corticosteroid use in neuro-oncology: an update","volume":"2","author":"Roth","year":"2015","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.ctrv.2024.102807_b0640","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0645","doi-asserted-by":"crossref","first-page":"1305720","DOI":"10.3389\/fonc.2024.1305720","article-title":"First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study","volume":"14","author":"Brown","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0650","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2014.12.011","article-title":"EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis","volume":"114","author":"Soon","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0655","doi-asserted-by":"crossref","first-page":"13304","DOI":"10.18632\/oncotarget.14515","article-title":"Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2024.102807_b0660","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2016.05.013","article-title":"EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases","volume":"11","author":"Jiang","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0665","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","article-title":"Brain metastases in EGFR- and ALK-positive NSCLC: Outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation","volume":"17","author":"Thomas","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0670","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.01.067","article-title":"Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey","volume":"93","author":"Levy","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0675","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10555-020-09949-9","article-title":"Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and\/or immunotherapy) in brain metastases: a systematic review","volume":"40","author":"Borius","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2024.102807_b0680","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0685","unstructured":"Dutch Trial Register. TKI concurrent with cerebral radiation therapy [in Dutch; TKI tegelijkertijd met bestraling van de hersenen], https:\/\/onderzoekmetmensen.nl\/en\/trial\/28884; 2022 [accessed May 2023]."},{"key":"10.1016\/j.ctrv.2024.102807_b0690","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.trsl.2022.08.005","article-title":"Radiation combined with KRAS-MEK inhibitors enhances anticancer immunity in KRAS-mutated tumor models","volume":"252","author":"Zheng","year":"2023","journal-title":"Transl Res"},{"key":"10.1016\/j.ctrv.2024.102807_b0695","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1186\/s12967-023-04619-0","article-title":"KRAS(G12C) inhibition using MRTX1257: a novel radio-sensitizing partner","volume":"21","author":"Laurent","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2024.102807_b0700","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","article-title":"Symptomatic necrosis with antibody-drug conjugates and concurrent stereotactic radiotherapy for brain metastases","volume":"9","author":"Lebow","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0705","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cllc.2021.06.009","article-title":"Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases: A systematic review and meta-analysis","volume":"23","author":"Yang","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0710","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/biomedicines10092249","article-title":"Efficacy and safety of combined brain stereotactic radiotherapy and immune checkpoint inhibitors in non-small-cell lung cancer with brain metastases","volume":"10","author":"Porte","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ctrv.2024.102807_b0715","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","article-title":"Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases","volume":"101","author":"Schapira","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl","key":"10.1016\/j.ctrv.2024.102807_b0720","first-page":"E465","article-title":"Lesion response and intracranial control of brain metastases from non\u2013small cell lung cancer after stereotactic radiosurgery or hypofractionated radiation therapy combined with checkpoint inhibitors [Abstract 3103]","volume":"99","author":"Imber","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102807_b0725","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2023.01.017","volume":"116","author":"Lehrer","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2024.102807_b0730","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","article-title":"Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation","volume":"4","author":"Martin","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0735","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/1759-7714.13048","article-title":"Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review","volume":"10","author":"Lin","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0740","article-title":"The abscopal effect: systematic review in patients with brain and spine metastases","author":"Pangal","year":"20224132","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ctrv.2024.102807_b0745","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","article-title":"Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): A nonrandomized, phase ii study","volume":"21","author":"Besse","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102807_b0750","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4137\/CMO.S8503","article-title":"Bevacizumab for the treatment of glioblastoma","volume":"7","author":"Gil-Gil","year":"2013","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0755","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2019.08.021","article-title":"EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases","volume":"121","author":"Jiang","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0760","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1179\/1973947815Y.0000000045","article-title":"Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer","volume":"28","author":"Fu","year":"2016","journal-title":"J Chemother"},{"key":"10.1016\/j.ctrv.2024.102807_b0765","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0770","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1002\/hsr2.115","article-title":"Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series","volume":"2","author":"Banks","year":"2019","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.ctrv.2024.102807_b0775","doi-asserted-by":"crossref","first-page":"682","DOI":"10.21037\/tlcr.2019.10.02","article-title":"Brain metastases from lung cancer with neuropsychiatric symptoms as the first symptoms","volume":"8","author":"Dong","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102807_b0780","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2004.05.128","article-title":"Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial","volume":"22","author":"Meyers","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0785","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102807_b0790","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.21037\/jtd-2019-rbmlc-11","article-title":"Supportive care for patients with brain metastases from lung cancer","volume":"13","author":"Sharma","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ctrv.2024.102807_b0795","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2020.11.003","article-title":"Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up","volume":"32","author":"Roth","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0800","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00066-022-01973-8","article-title":"Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment","volume":"198","author":"Bernhardt","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ctrv.2024.102807_b0805","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/ijms17122132","article-title":"EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer","volume":"17","author":"Tomasini","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102807_b0810","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12885-022-09317-6","article-title":"Recurrent brain metastases: the role of resection of in a comprehensive multidisciplinary treatment setting","volume":"22","author":"He\u00dfler","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0815","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.1038\/s41598-022-13853-3","article-title":"Clinical outcomes of patients with multiple courses of radiosurgery for brain metastases from non-small cell lung cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2024.102807_b0820","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3171\/2022.4.JNS212597","article-title":"Adverse radiation effect and freedom from progression following repeat stereotactic radiosurgery for brain metastases","volume":"138","author":"Sneed","year":"2023","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2024.102807_b0825","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-023-04407-2","article-title":"The evolving role of reirradiation in the management of recurrent brain tumors","volume":"164","author":"De Pietro","year":"2023","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0830","first-page":"vdad031","article-title":"Efficacy of laser interstitial thermal therapy for biopsy-proven radiation necrosis in radiographically recurrent brain metastases","volume":"5","author":"Chan","year":"2023","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ctrv.2024.102807_b0835","article-title":"Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases","volume":"4: vdac086","author":"Grabowski","year":"2022","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ctrv.2024.102807_b0840","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ctrv.2016.12.006","article-title":"Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era","volume":"53","author":"Remon","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102807_b0845","first-page":"41","article-title":"Leptomeningeal metastases from non-small cell lung cancer: State of the art and recent advances","volume":"6","author":"Pellerino","year":"2020","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.ctrv.2024.102807_b0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2024.102807_b0855","doi-asserted-by":"crossref","first-page":"e2120040","DOI":"10.1001\/jamanetworkopen.2021.20040","article-title":"Detection of leptomeningeal disease using cell-free DNA from cerebrospinal fluid","volume":"4","author":"White","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctrv.2024.102807_b0860","doi-asserted-by":"crossref","first-page":"e000507","DOI":"10.1136\/esmoopen-2019-000507","article-title":"How we treat patients with leptomeningeal metastases","volume":"4","author":"Le Rhun","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2024.102807_b0865","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JTO.0b013e318287c943","article-title":"Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer","volume":"8","author":"Gwak","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0870","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0875","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","article-title":"Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors","volume":"8","author":"Lee","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0880","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0885","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0890","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cllc.2013.12.009","article-title":"Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era","volume":"15","author":"Riess","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0895","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM Study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0900","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: The AURA Leptomeningeal Metastases Analysis","volume":"15","author":"Ahn","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0905","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","article-title":"Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors","volume":"23","author":"Le Rhun","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0910","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0915","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11864-020-00759-3","article-title":"Leptomeningeal metastases in non-small cell lung cancer: optimal systemic management in NSCLC with and without driver mutations","volume":"21","author":"Alexander","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0920","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.1038\/s41467-021-25859-y","article-title":"Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis","volume":"12","author":"Brastianos","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2024.102807_b0925","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2019.05.019","article-title":"Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors","volume":"116","author":"Hendriks","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b0930","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.22.01148","article-title":"Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis","volume":"40","author":"Yang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0935","article-title":"Clinical trial eligibility criteria and recently approved cancer therapies for patients with brain metastases","volume":"11","author":"Tan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0940","unstructured":"US Food and Drug Administration. Cancer clinical trial eligibility criteria: Brain metastases guidance for industry, https:\/\/www.fda.gov\/media\/121317\/download; 2020 [accessed February 2023]."},{"key":"10.1016\/j.ctrv.2024.102807_b0945","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1200\/JCO.2017.74.0761","article-title":"Modernizing clinical trial eligibility criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group","volume":"35","author":"Lin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0950","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.3390\/cancers13112645","article-title":"Molecular profiles of brain metastases: A focus on heterogeneity","volume":"13","author":"Ali","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102807_b0955","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S1470-2045(17)30692-7","article-title":"Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group","volume":"19","author":"Alexander","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0960","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jon.12460","article-title":"Role of FDG-PET\/MRI, FDG-PET\/CT, and dynamic susceptibility contrast perfusion MRI in differentiating radiation necrosis from tumor recurrence in glioblastomas","volume":"28","author":"Hojjati","year":"2018","journal-title":"J Neuroimaging"},{"key":"10.1016\/j.ctrv.2024.102807_b0965","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.radonc.2022.10.026","article-title":"Diagnostic accuracy of MRI techniques for treatment response evaluation in patients with brain metastasis: A systematic review and meta-analysis","volume":"177","author":"Teunissen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0970","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/neuonc\/noz003","article-title":"PET imaging in patients with brain metastasis-report of the RANO\/PET group","volume":"21","author":"Galldiks","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b0975","article-title":"Current status of PET imaging in neuro-oncology","volume":"1: vdz010","author":"Galldiks","year":"2019","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ctrv.2024.102807_b0980","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/bioengineering5040104","article-title":"The emerging role of amino acid PET in neuro-oncology","volume":"5","author":"Najjar","year":"2018","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.ctrv.2024.102807_b0985","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13244-020-00888-1","article-title":"Multiparametric MRI: practical approach and pictorial review of a useful tool in the evaluation of brain tumours and tumour-like lesions","volume":"11","author":"Sawlani","year":"2020","journal-title":"Insights Imaging"},{"key":"10.1016\/j.ctrv.2024.102807_b0990","unstructured":"US Food and Drug Administration. Evaluating cancer drugs in patients with central nervous system metastases \u2013 guidance for industry (2021), https:\/\/www.fda.gov\/media\/141507\/download; 2021 [accessed April 2024]."},{"key":"10.1016\/j.ctrv.2024.102807_b0995","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b1000","doi-asserted-by":"crossref","first-page":"CNS28","DOI":"10.2217\/cns-2018-0007","article-title":"Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice","volume":"8","author":"Chukwueke","year":"2019","journal-title":"CNS Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b1005","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b1010","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b1015","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/jmri.27741","article-title":"Fully automated MR detection and segmentation of brain metastases in non-small cell lung cancer using deep learning","volume":"54","author":"Junger","year":"2021","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.ctrv.2024.102807_b1020","article-title":"Automated detection and quantification of brain metastases on clinical MRI data using artificial neural networks","author":"Pfluger","year":"20224138","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ctrv.2024.102807_b1025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/neuonc\/noac189","article-title":"Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study","volume":"25","author":"Vollmuth","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b1030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/annonc\/mdy544","article-title":"Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases","volume":"30","author":"Seoane","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107292","article-title":"Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer","volume":"182","author":"Tsakonas","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b1040","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12916-022-02595-8","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.ctrv.2024.102807_b1045","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/neuonc\/noaa149","article-title":"Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review","volume":"22","author":"Vogelbaum","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b1050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2022.02.006","article-title":"EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature","volume":"166","author":"Copia Sperandio","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b1055","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/0284186X.2021.1973092","article-title":"Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study","volume":"60","author":"Eide","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b1060","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtho.2021.11.025","article-title":"A Phase 1\/2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors","volume":"17","author":"Cho","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b1065","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: Outcomes in patient subgroups from the VISION Study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102807_b1070","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations","volume":"18","author":"Paz-Ares","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102807_b9020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102807_b1075","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1556-0864(23)00264-2","article-title":"10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) \u226550% \u2014 3-year update","volume":"18","author":"Kilickap","year":"2023","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722400135X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722400135X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T18:14:49Z","timestamp":1729016089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722400135X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":216,"alternative-id":["S030573722400135X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102807","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102807"}}